Actively Recruiting
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Led by University of Wisconsin, Madison · Updated on 2026-04-14
298
Participants Needed
3
Research Sites
178 weeks
Total Duration
On this page
Sponsors
U
University of Wisconsin, Madison
Lead Sponsor
N
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This protocol describes a randomized controlled trial testing the effectiveness and implementability of the CHESS Health Connections smartphone application among patients with alcohol-associated liver disease (ALD) at two medical centers in Michigan and Wisconsin, in two types of clinics: general hepatology and multidisciplinary that offers care for advanced ALD alongside co-located, integrated mental health and substance abuse treatment. The long-term goal of this and future work is to prevent disease progression and promote healthy behaviors by improving the rate of abstinence among patients with ALD earlier in the course of their disease. 298 participants will be enrolled and can expect to be on study for up to 6 months.
CONDITIONS
Official Title
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
Diagnosis of ALD (any stage)
-
Alcoholic liver disease (ALD) encompasses a spectrum of hepatic injuries caused by long-term alcohol abuse. For this study, participants will have a diagnosis of ALD or evidence of the combination of liver disease and alcohol misuse in electronic health record.
-
Alcohol use within the last 6 months
-
Receiving care at UW or Henry Ford Health + MSU
- Either the general hepatology clinic or the multidisciplinary ALD clinic
-
Able to read and write proficiently in English
-
Willing and able to use a smartphone app
You will not qualify if you...
- Actively listed for liver transplant or history of liver transplant before being enrolled in the study. Participants added to a liver transplant list after being enrolled in the study will be allowed to continue their participation
- In hospice care
- Has severe cognitive impairment (as described in electronic health record including dementia, delirium, and/or unable to maintain cognitive alertness during screening--as determined by study staff.)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Henry Ford + Michigan State University Health Center
Lansing, Michigan, United States, 48824
Actively Recruiting
2
UW General Hepatology Clinic
Madison, Wisconsin, United States, 53705
Actively Recruiting
3
UW Multidisciplinary ALD Clinic
Madison, Wisconsin, United States, 53705
Actively Recruiting
Research Team
J
Jared P McDonald, MBA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here